Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Covington
US Department of Justice
Chubb
McKesson
Farmers Insurance
Baxter
Merck

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

« Back to Dashboard

Clinical Trials for Primacor In Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Summary
NCT00543309 Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery Terminated American Heart Association Phase 2 The staged surgical pathway to treat children with single ventricle heart defects culminates with the Fontan operation. In this procedure, systemic venous return is rerouted directly to the pulmonary arteries, which serves to separate the systemic and pulmonary circulations. Although mortality following the Fontan operation is now uncommon, early postoperative morbidity including prolonged postoperative chest tube drainage and hospitalization remains significant. The efficacy of empiric inotropic, vasodilator and neurohumoral-inhibitory therapies in the perioperative period is unknown and practice varies widely between centers. The investigators will propose a single-center, randomized, double-blind, phase II clinical trial in children undergoing Fontan surgery. The investigators plan to compare the effects of perioperative nesiritide, milrinone and placebo infusions on the early postoperative clinical course and neurohumoral profile. The investigators hypothesize that, when compared to the milrinone and placebo groups, the nesiritide group will have more days alive and out of the hospital within the first 30 days after surgery.
NCT00543309 Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery Terminated John M Costello Phase 2 The staged surgical pathway to treat children with single ventricle heart defects culminates with the Fontan operation. In this procedure, systemic venous return is rerouted directly to the pulmonary arteries, which serves to separate the systemic and pulmonary circulations. Although mortality following the Fontan operation is now uncommon, early postoperative morbidity including prolonged postoperative chest tube drainage and hospitalization remains significant. The efficacy of empiric inotropic, vasodilator and neurohumoral-inhibitory therapies in the perioperative period is unknown and practice varies widely between centers. The investigators will propose a single-center, randomized, double-blind, phase II clinical trial in children undergoing Fontan surgery. The investigators plan to compare the effects of perioperative nesiritide, milrinone and placebo infusions on the early postoperative clinical course and neurohumoral profile. The investigators hypothesize that, when compared to the milrinone and placebo groups, the nesiritide group will have more days alive and out of the hospital within the first 30 days after surgery.
NCT01621971 Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients Completed Konkuk University Medical Center Phase 3 Our main hypothesis is that inhalation of milrinone can reduce the elevated pulmonary arterial pressure due to severe mitral valve regurgitation without compromising systemic hemodynamics. Therefore, the effects of a brief inhaled milrinone (IH) on pulmonary artery pressure are determined and compared to those of intravenous milrinone (IV) in severe mitral regurgitation patients undergoing mitral valve surgery.
NCT01725776 Inhaled Milrinone in Cardiac Surgery Completed Canadian Institutes of Health Research (CIHR) Phase 2 The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
NCT01725776 Inhaled Milrinone in Cardiac Surgery Completed Fonds de la Recherche en Santé du Québec Phase 2 The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
NCT01725776 Inhaled Milrinone in Cardiac Surgery Completed St. Justine's Hospital Phase 2 The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
NCT01725776 Inhaled Milrinone in Cardiac Surgery Completed Montreal Heart Institute Phase 2 The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Primacor In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Primacor In Dextrose 5% In Plastic Container
Intervention Trials
Pulmonary Hypertension 3
Heart Defects, Congenital 1
Persistent Pulmonary Hypertension of the Newborn 1
Congenital Diaphragmatic Hernia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Primacor In Dextrose 5% In Plastic Container
Intervention Trials
Hypertension, Pulmonary 4
Hypertension 3
Heart Failure 2
Heart Defects, Congenital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Primacor In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Primacor In Dextrose 5% In Plastic Container
Location Trials
United States 14
China 1
Canada 1
Korea, Republic of 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Primacor In Dextrose 5% In Plastic Container
Location Trials
Iowa 1
Georgia 1
California 1
Alabama 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Primacor In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Primacor In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1/Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Primacor In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Suspended 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Primacor In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Primacor In Dextrose 5% In Plastic Container
Sponsor Trials
John M Costello 1
Lipscomb University 1
Assiut University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Primacor In Dextrose 5% In Plastic Container
Sponsor Trials
Other 15
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
UBS
Teva
US Department of Justice
Farmers Insurance
US Army
Queensland Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.